BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells-Reference-Cited by-同舟云学术

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Published:2019-02-14 Issue:9 Volume:25 Page:2783-2794
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Atay Cigdem,Kwak Taekyoung,Lavilla-Alonso Sergio,Donthireddy Laxminarasimha,Richards Allison,Moberg Valerie,Pilon-Thomas Shari,Schell Michael,Messina Jane L.^ORCID,Rebecca Vito W.,Xiao Min,Tan Jiufeng,Zhang Gao,Weber Jeffrey S.,Herlyn Meenhard,Sarnaik Amod A.,Gabrilovich Dmitry I.

Funder

HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI)

American Cancer SocietyAmerican Cancer Society (ACS)

Dr. Miriam and Sheldon G. Adelson Medical Research FoundationDr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)

U.S. Department of DefenseU.S. Department of Defense (DOD)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-infiltrating lymphocytes: A new hope;Cancer Cell;2024-08

2. Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib;Biochemical Pharmacology;2024-01

3. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity;Cell Reports;2023-10

4. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies;Journal of Translational Medicine;2023-09-09

5. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies;J TRANSL MED;2023